Manufacturer of Controlled Substances; Notice of Registration, 34040-34041 [E7-11916]
Download as PDF
<![CDATA[
34040
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–11910 Filed 6–19–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on April 23, 2007, Cambrex Charles
City, Inc., 1205 11th Street, Charles City,
Iowa 50616–3466, made application by
letter to the Drug Enforcement
Administration (DEA) for registration as
an importer of the basic classes of
controlled substances listed in
schedules II:
Drug
rwilkins on PROD1PC63 with NOTICES
BILLING CODE 4410–09–P
II
II
II
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
The company plans to import the
listed controlled substances for
manufacture of active pharmaceutical
ingredients for sale to its customers.
No comments, objections, or requests
for any hearings will be received on any
application for registration or reregistration to import crude opium,
poppy straw, concentrate of poppy
straw, and coca leaves.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
may be addressed, in quintuplicate, to
the Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537; or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL), 2401
Jefferson-Davis Highway, Alexandria,
18:25 Jun 19, 2007
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–11915 Filed 6–19–07; 8:45 am]
Schedule
Thebaine (9333) ...........................
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
VerDate Aug<31>2005
Virginia 22301; and must be filed no
later than July 20, 2007.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e) and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, (40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Jkt 211001
Importer of Controlled Substances;
Notice of Application
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on May 16, 2006, Chattem
Chemicals, Inc., 3801 St. Elmo Avenue,
Building 18, Chattanooga, Tennessee
37409, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
Methamphetamine (1105) ............
Phenylacetone (8501) ..................
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
II
II
II
II
The company plans to import the
listed controlled substances to
manufacture bulk controlled substances
for sale to its customers.
No comments, objections, or requests
for any hearings will be received on any
application for registration or reregistration to import crude opium [Raw
Opium (9600)], poppy straw,
concentrate of poppy straw, and coca
leaves.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B) may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
may be addressed, in quintuplicate, to
the Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537; or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL), 2401
Jefferson Davis Highway, Alexandria,
Virginia 22301; and must be filed no
later than July 20, 2007.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e) and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, (40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–11914 Filed 6–19–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated November 21, 2006,
and published in the Federal Register
on December 1, 2006, (71 FR 69593),
Noramco Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Oxymorphone (9652), a basic class of
controlled substance listed in schedule
II.
E:\FR\FM\20JNN1.SGM
20JNN1
34041
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
The company plans to manufacture
for in-house dosage form production
and for sales to other dosage form
manufacturers.
When the company first submitted
their application, the company
submitted information to DEA that the
firm would be manufacturing
Oxymorphone for in-house dosage form
production and sales to other dosage
form manufacturers. Upon further
investigation by the DEA it was
uncovered that the company would only
be producing bulk material for dosage
form manufacturers. DEA will grant this
registration for the production of bulk
manufacturing of Oxymorphone.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco Inc. to manufacture the listed
basic class of controlled substance is
consistent with the public interest at
this time. DEA has investigated
Noramco Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–11916 Filed 6–19–07; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
rwilkins on PROD1PC63 with NOTICES
Manufacturer of Controlled
Substances; Notice of Registration
Jkt 211001
Lysergic acid diethylamide (LSD)
(7315).
4-Methoxyamphetamine (7411) ...
Normorphine (9313) .....................
Tetrahydrocannabinols
(THC)
(7370).
Alphamethadol (9605) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Cocaine (9041) .............................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oxycodone (9143) ........................
Meperidine (9230) ........................
Methadone (9250) ........................
Oxymorphone (9652) ...................
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
to manufacture controlled substance
derivatives. These derivatives will be
used in diagnostic products created
specifically for internal use only.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Orasure Technologies, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Orasure Technologies, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
BILLING CODE 4410–09–P
63021–4500, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
I:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Schedule
I
I
The company plans to import the
above listed synthetic products for nonclinical laboratory based research only.
In reference to drug code 7360
(Marihuana), the company plans to
import synthetic cannabidiol. In
reference to drug code 7370
(Tetrahydrocannabinols), the company
plans to import synthetic THC.
No other activity for this drug code is
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Tocris Cookson, Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Tocris
Cookson, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control,Drug Enforcement
Administration.
[FR Doc. E7–11912 Filed 6–19–07; 8:45 am]
BILLING CODE 4410–09–P
By Notice dated February 5, 2007, and
published in the Federal Register on
February 12, 2007, (72 FR 6579),
Orasure Technologies, Inc., Lehigh
University, Seeley G. Mudd-Building 6,
220 East First Street, Bethlehem,
Pennsylvania 18015, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedule I and II:
18:25 Jun 19, 2007
Schedule
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator,Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–11907 Filed 6–19–07; 8:45 am]
DEPARTMENT OF JUSTICE
VerDate Aug<31>2005
Drug
DEPARTMENT OF JUSTICE
DEPARTMENT OF LABOR
Drug Enforcement Administration
Office of the Secretary
Importer of Controlled Substances;
Notice of Registration
By Notice dated March 19, 2007 and
published in the Federal Register on
March 27, 2007, (72 FR 14297), Tocris
Cookson, Inc., 16144 Westwoods
Business Park, Ellisville, Missouri
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
Submission for OMB Review:
Comment Request
June 13, 2007.
The Department of Labor (DOL) has
submitted the following public
information collection request (ICR) to
E:\FR\FM\20JNN1.SGM
20JNN1
]]>Agencies
[Federal Register Volume 72, Number 118 (Wednesday, June 20, 2007)]
[Notices]
[Pages 34040-34041]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-11916]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated November 21, 2006, and published in the Federal
Register on December 1, 2006, (71 FR 69593), Noramco Inc., 1440 Olympic
Drive, Athens, Georgia 30601, made application by letter to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of Oxymorphone (9652), a basic class of controlled
substance listed in schedule II.
[[Page 34041]]
The company plans to manufacture for in-house dosage form
production and for sales to other dosage form manufacturers.
When the company first submitted their application, the company
submitted information to DEA that the firm would be manufacturing
Oxymorphone for in-house dosage form production and sales to other
dosage form manufacturers. Upon further investigation by the DEA it was
uncovered that the company would only be producing bulk material for
dosage form manufacturers. DEA will grant this registration for the
production of bulk manufacturing of Oxymorphone.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Noramco Inc. to manufacture the listed basic class of controlled
substance is consistent with the public interest at this time. DEA has
investigated Noramco Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic class of controlled substance listed.
Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-11916 Filed 6-19-07; 8:45 am]
BILLING CODE 4410-09-P
